
Estimated delivery: 2–5 business days. Delivery times may vary.
Orders of $500 or more ship free. Final shipping details at checkout.
$119.99
SEMA / IGF-1 LR3 denotes a proposed semaglutide–growth-factor combination. Semaglutide is studied for GLP-1-mediated metabolic effects, while LR3 IGF-1 supports growth signaling in laboratory systems; blend-specific claims require separate attribution. For research use only; not for human or veterinary use.
Educational research context. The cited studies and supplier descriptions do not verify the identity, testing, or effects of this Heritage product.
SEMA is a common abbreviation for semaglutide, a GLP-1 receptor agonist. IGF-1 LR3 is a modified form of insulin-like growth factor 1 used as a growth-promoting laboratory reagent. These components address different signaling systems: the semaglutide literature concerns metabolic regulation and body weight, whereas LR3 documentation emphasizes receptor-mediated cell survival and proliferation. The combined label does not identify a naturally occurring hormone or an approved fixed-combination medicine.
The STEP 1 trial studied semaglutide with lifestyle intervention in adults with overweight or obesity and reported greater average weight reduction than placebo. That study did not include IGF-1 LR3. GroPep’s LR3 product information concerns cell-culture supplementation rather than preservation of human muscle during semaglutide-associated weight loss. A possible body-composition rationale can be inferred from the pairing, but no exact Umbrella blend page or blend-specific trial was established in this review. Accordingly, descriptions such as fat loss with muscle support would need to be presented as a proposed combination concept, not as an outcome demonstrated by either component source.
For research use only. Not for human or veterinary use; not medical advice.